GTx, Inc. (NASDAQ:GTXI)’s share price traded down 7.7% during mid-day trading on Friday . The company traded as low as $1.50 and last traded at $1.55. 614,986 shares traded hands during trading, a decline of 18% from the average session volume of 747,045 shares. The stock had previously closed at $1.68.

A number of equities analysts have issued reports on the company. Zacks Investment Research raised GTX from a “hold” rating to a “buy” rating and set a $1.75 price target for the company in a research note on Tuesday, October 16th. ValuEngine lowered GTX from a “buy” rating to a “hold” rating in a research note on Saturday, September 22nd. Stifel Nicolaus lowered GTX from a “buy” rating to a “hold” rating in a research note on Friday, September 21st. Robert W. Baird lowered GTX from an “outperform” rating to a “neutral” rating and set a $17.00 price target for the company. in a research note on Friday, September 21st. Finally, BidaskClub lowered GTX from a “buy” rating to a “hold” rating in a research note on Thursday, September 20th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $21.25.

GTX (NASDAQ:GTXI) last announced its quarterly earnings data on Monday, October 22nd. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.09). As a group, analysts anticipate that GTx, Inc. will post -1.65 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in GTXI. Candriam Luxembourg S.C.A. acquired a new stake in shares of GTX during the 3rd quarter valued at $410,000. BlackRock Inc. lifted its position in shares of GTX by 129.5% during the 2nd quarter. BlackRock Inc. now owns 390,150 shares of the biopharmaceutical company’s stock valued at $5,973,000 after acquiring an additional 220,114 shares during the last quarter. Millennium Management LLC lifted its position in shares of GTX by 107.0% during the 1st quarter. Millennium Management LLC now owns 121,957 shares of the biopharmaceutical company’s stock valued at $2,165,000 after acquiring an additional 63,051 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of GTX by 57.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 170,250 shares of the biopharmaceutical company’s stock valued at $2,607,000 after acquiring an additional 62,250 shares during the last quarter. Finally, Federated Investors Inc. PA lifted its position in shares of GTX by 68.1% during the 2nd quarter. Federated Investors Inc. PA now owns 147,539 shares of the biopharmaceutical company’s stock valued at $2,259,000 after acquiring an additional 59,754 shares during the last quarter. Institutional investors own 28.52% of the company’s stock.

WARNING: “GTX (GTXI) Shares Down 7.7%” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/gtx-gtxi-shares-down-7-7/2600923.html.

GTX Company Profile (NASDAQ:GTXI)

GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.